<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969901</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-021</org_study_id>
    <secondary_id>MK-7655A-021</secondary_id>
    <secondary_id>2019-000338-20</secondary_id>
    <nct_id>NCT03969901</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)</brief_title>
  <official_title>A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and tolerability of&#xD;
      imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of&#xD;
      age with confirmed or suspected gram-negative bacterial infection. Participants are expected&#xD;
      to require hospitalization through completion of intravenous (IV) study intervention, and&#xD;
      have at least one of the following primary infection types: hospital-acquired bacterial&#xD;
      pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated&#xD;
      intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI). Participants&#xD;
      will be randomized in a 3:1 ratio to receive IMI/REL or active control. This study will also&#xD;
      evaluate the efficacy of IMI/REL by assessing all-cause mortality at Day 28&#xD;
      post-randomization, as well as clinical and microbiological response to treatment. It will&#xD;
      also evaluate the pharmacokinetics of IMI/REL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">November 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Adverse Event (AE)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with AEs will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study medication due to an AE will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths by All Causes Through Day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>All-cause mortality up to 28 days post-randomization will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at End of Therapy (EOT)</measure>
    <time_frame>Day 5 up to Day 14</time_frame>
    <description>The percentage of participants with a favorable clinical response at EOT will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Early Follow-Up (EFU)</measure>
    <time_frame>Day 12 up to Day 28</time_frame>
    <description>The percentage of participants with a favorable clinical response at EFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Late Follow-Up (LFU)</measure>
    <time_frame>Day 19 up to Day 42</time_frame>
    <description>The percentage of participants with a favorable clinical response at LFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at End of Therapy (EOT)</measure>
    <time_frame>Day 5 up to Day 14</time_frame>
    <description>The percentage of participants with a favorable microbiological response at EOT will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at End of Follow-Up (EFU)</measure>
    <time_frame>Day 12 up to Day 28</time_frame>
    <description>The percentage of participants with a favorable microbiological response at EFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at Late Follow-Up (LFU)</measure>
    <time_frame>Day 19 up to Day 42</time_frame>
    <description>Percentage of participants with a favorable microbiological response at LFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Imipenem Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for AUC0-24 of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Relebactam Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for AUC0-24 of relebactam analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at End of Infusion (Ceoi) of Imipenem Following Administration of IMI/REL</measure>
    <time_frame>At the end of the first infusion on Day 1.</time_frame>
    <description>Blood samples for Ceoi of imipenem analysis will be collected within 10 minutes after the end of the first infusion on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at End of Infusion (Ceoi) of Relabactam Following Administration of IMI/REL</measure>
    <time_frame>At the end of the first infusion on Day 1.</time_frame>
    <description>Blood samples for Ceoi of relabactam analysis will be collected within 10 minutes after the end of the first infusion on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Imipenem Concentration Is Above Minimum Inhibitory Concentration (%T&gt;MIC of Imipenem) Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for %T&gt;MIC of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Suspected or Documented Gram-negative Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>IMI/REL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMI/REL</intervention_name>
    <description>Age-based dosing:&#xD;
12 to &lt;18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours&#xD;
2 to &lt;12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours&#xD;
3 months to &lt;2 years, to be determined (TBD)&#xD;
Birth to &lt;3 months (TBD) NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.</description>
    <arm_group_label>IMI/REL</arm_group_label>
    <other_name>MK-7655A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Control</intervention_name>
    <description>All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.&#xD;
NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Requires hospitalization and treatment with IV antibacterial therapy for confirmed or&#xD;
             suspected gram-negative bacterial infection (in the absence of meningitis), and is&#xD;
             expected to require hospitalization through completion of IV study intervention, with&#xD;
             at least 1 of the following primary infection types: HABP or VABP; cIAI; or cUTI.&#xD;
&#xD;
          -  For Age Cohorts 4 and 5, participant is at least 37 weeks postmenstrual age at the&#xD;
             time of signing the informed consent.&#xD;
&#xD;
          -  If female, must not be pregnant or breastfeeding, and at least 1 of the following&#xD;
             conditions must apply: must not be a woman of childbearing potential (WOCBP); OR, if a&#xD;
             WOCBP, must agree to follow contraceptive guidance during the intervention period and&#xD;
             for at least 24 hours after the last dose of study intervention.&#xD;
&#xD;
          -  Has sufficient intravascular access to receive study drug through an existing&#xD;
             peripheral or central line.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is expected to survive less than 72 hours.&#xD;
&#xD;
          -  Has a concurrent infection that would interfere with evaluation of response to the&#xD;
             study antibacterials (IMI/REL or Active Control), including any of the following:&#xD;
             endocarditis; osteomyelitis; meningitis; prosthetic joint infection; active pulmonary&#xD;
             tuberculosis; disseminated fungal infection; concomitant infection at the time of&#xD;
             randomization that requires non-study systemic antibacterial therapy in addition to IV&#xD;
             study treatment or oral step-down therapy.&#xD;
&#xD;
          -  Has HABP/VABP caused by an obstructive process, including lung cancer (or other&#xD;
             malignancy metastatic to the lungs resulting in pulmonary obstruction) or other known&#xD;
             obstruction.&#xD;
&#xD;
          -  Has a cUTI, with any of the following: complete obstruction of any portion of the&#xD;
             urinary tract (ie, requiring a permanent indwelling urinary catheter or&#xD;
             instrumentation); documented ileal loop reflux; suspected or confirmed perinephric or&#xD;
             intrarenal abscess; suspected or confirmed prostatitis, urethritis, or epididymitis;&#xD;
             trauma to pelvis/urinary tract; presence of indwelling urinary catheter which cannot&#xD;
             be removed at study entry.&#xD;
&#xD;
          -  Has any of the following medical conditions at screening: history of a seizure&#xD;
             disorder (requiring ongoing treatment with anti-convulsive therapy or prior treatment&#xD;
             with anti-convulsive therapy within the last 3 years); cystic fibrosis; history of&#xD;
             serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to IMI,&#xD;
             or to any carbapenem, cephalosporin, penicillin, or other β-lactam agent, or to other&#xD;
             β-lactamase inhibitors (eg, tazobactam, sulbactam, clavulanic acid, avibactam).&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, laboratory abnormality,&#xD;
             or other circumstance that might expose the participant to risk by participating in&#xD;
             the study, confound study results, or interfere with the participant's participation&#xD;
             for the full duration of the study.&#xD;
&#xD;
          -  If less than 3 months of age, has received more than 72 hours of empiric antibacterial&#xD;
             treatment until meningitis has been ruled out prior to initiation of IV study&#xD;
             intervention.&#xD;
&#xD;
          -  If 3 months of age or older, has received potentially therapeutic antibacterial&#xD;
             therapy (eg, with gram-negative activity), including bladder infusions with topical&#xD;
             urinary antiseptics or antibacterial agents, for a duration of more than 24 hours&#xD;
             during the 48 hours preceding the first dose of study intervention.&#xD;
&#xD;
          -  Is anticipated to be treated with any of the following medications: valproic acid or&#xD;
             divalproex sodium (or has used valproic acid or divalproex sodium in the 2 weeks prior&#xD;
             to screening) through 24 hours after completion of the final dose of IV study&#xD;
             intervention for participants who receive IMI/REL or carbapenem; concomitant IV, oral,&#xD;
             or inhaled antimicrobial agents with gram-negative activity, in addition to those&#xD;
             designated in the study intervention groups, during the course of all (IV/oral) study&#xD;
             intervention; planned receipt of suppressive/prophylactic antibiotics with&#xD;
             gram-negative activity after completion of study intervention.&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical study&#xD;
             with an investigational compound or device within 30 days prior to screening.&#xD;
&#xD;
          -  Has enrolled previously in the current study and been discontinued, or has received&#xD;
             REL for any other reason.&#xD;
&#xD;
          -  Has an estimated creatinine clearance (based on the Cockcroft-Gault equation, for&#xD;
             participants ≥12 years of age) or estimated glomerular filtration rate (eGFR, based on&#xD;
             the modified Schwartz equation, for participants &lt;12 years of age) below that&#xD;
             specified for the appropriate age range; or requires peritoneal dialysis,&#xD;
             hemodialysis, or hemofiltration.&#xD;
&#xD;
          -  Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × upper&#xD;
             limit of normal (ULN) at the time of screening. NOTE: Patients with acute hepatic&#xD;
             failure or acute decompensation of chronic hepatic failure should also be excluded.&#xD;
&#xD;
          -  Is a user of recreational or illicit drugs or has had a recent history of drug or&#xD;
             alcohol abuse or dependence.&#xD;
&#xD;
          -  Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or&#xD;
             child) who is investigational site or Sponsor staff directly involved with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center ( Site 0356)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-237-6845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miller Children's &amp; Women's Hospital ( Site 0349)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806-1737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 0347)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-966-8381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center-Floating Hospital for Children ( Site 0350)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-636-0186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico ( Site 0358)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-269-3630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital ( Site 0360)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-567-5262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU ( Site 0359)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University Ruby Memorial Hospital ( Site 0344)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>304-293-1201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Deva Maria. EOOD ( Site 0165)</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35956896282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT City Clinic Sv. Georgi EOOD ( Site 0167)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887397013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski EAD ( Site 0174)</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359886845270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 0168)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359899975275</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 0169)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888209200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Ival Seliminski ( Site 0173)</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35944611700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital San Vicente de Paul ( Site 0269)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573104262042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0264)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157609110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0265)</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>1100100</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573207532651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Infantil Universitario de San Jose ( Site 0268)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573108059791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0266)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573154896219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterand ( Site 0146)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380295892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne de Flandre ( Site 0145)</name>
      <address>
        <city>Lille</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59120</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33320446059</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0189)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247774810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hebrew University Medical Center ( Site 0188)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center ( Site 0187)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239253779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0190)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235305978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tijuana ( Site 0284)</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5216646840210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Nino y Adolescente Morelense ( Site 0286)</name>
      <address>
        <city>Emiliano Zapata</city>
        <state>Morelos</state>
        <zip>62765</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 0290)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20259</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+524499946720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0291)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssjukehus ( Site 0500)</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4755975200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Philippines-Philippine General Hospital ( Site 0318)</name>
      <address>
        <city>Manila</city>
        <state>National Capital Region</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639186047003</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippine Children s Medical Center ( Site 0317)</name>
      <address>
        <city>Quezon City</city>
        <state>National Capital Region</state>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639470142467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. Rydgiera ( Site 0220)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48566794601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki ( Site 0223)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422711391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0226)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 0233)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Morozovskaya Children City Clinical Hospital ( Site 0241)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79255858745</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Novosibirsk Region City Childrens Clinical Emergency Hospi</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast</state>
        <zip>630011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>73832232358</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 0236)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's City Clinical Hospital #1 ( Site 0237)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children s City Clinical Hospital 5 n.a. N.F. Filatov ( Site 0235)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>192289</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124000410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 0231)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107896781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital ( Site 0400)</name>
      <address>
        <city>Vologda</city>
        <state>Vologodskaya Oblast</state>
        <zip>160022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 0156)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119330270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empilweni Services and Research Unit ( Site 1557)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2093</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27114709000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Molotlegi Street ( Site 0155)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27125215633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus ( Site 0114)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0113)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34912071551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 0115)</name>
      <address>
        <city>Sevilla</city>
        <zip>41043</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34955013767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty ( Site 0200)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326534166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi. ( Site 0202)</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903125956539</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi University Medical ( Site 0201)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905339243269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 0198)</name>
      <address>
        <city>Istanbul</city>
        <zip>34453</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tıp Fakultesi Hastanesi ( Site 0199)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323901427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 0121)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509142649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PI Kryvorizka city clinical hospital 8 of Dnipropetrovsk Reg Council ( Site 0128)</name>
      <address>
        <city>Kryvyy Rig</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50082</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380676339039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital ( Site 0131)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380681040592</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Children Hospital 16 ( Site 0130)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380662571720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Enterprise Children's City Clinical Hospital in Poltava City Council ( Site 0122)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509649499</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Relebactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

